Home/Pipeline/SENTI-202

SENTI-202

Acute Myeloid Leukemia (AML)

Phase 1Active, global clinical trial

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1

Status

Active, global clinical trial

Company

Senti Biosciences

About Senti Biosciences

Senti Biosciences is leveraging its proprietary Gene Circuit platform to develop a new generation of intelligent cell therapies, primarily for oncology. The company's lead candidate, SENTI-202, is in a Phase 1 trial for acute myeloid leukemia (AML) and has shown positive preliminary efficacy. Senti's strategy combines advancing its wholly-owned pipeline with exploring platform applications in other modalities and diseases through partnerships.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active